standard of care in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-TOCI-ICU (Group 2), 2020 (REV) 1.56 [0.56; 4.40]
Talaschian, 2021 (REV) 0.64 [0.14; 2.92]
Veiga, 2021 (REV) 0.37 [0.13; 1.09]
0.74 [0.29 ; 1.85 ] CORIMUNO-TOCI-ICU (Group 2), 2020 (REV), Talaschian, 2021 (REV), Veiga, 2021 (REV) 3 45% 257 moderate not evaluable deathsdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1.08 [0.37; 3.19]
CORIMUNO-TOCI-ICU (Group 2), 2020 (REV) 1.56 [0.56; 4.40]
REMAP-CAP (tocilizumab), 2021 (REV) 1.43 [1.05; 1.95]
Talaschian, 2021 (REV) 0.80 [0.19; 3.29]
Veiga, 2021 (REV) 0.37 [0.13; 1.09]
1.08 [0.67 ; 1.75 ] CORIMUNO-TOCI-1 (Group 1), 2020 (REV), CORIMUNO-TOCI-ICU (Group 2), 2020 (REV), REMAP-CAP (tocilizumab), 2021 (REV), Talaschian, 2021 (REV), Veiga, 2021 (REV) 5 36% 1,138 moderate not evaluable deaths (time to event analysis only)detailed results Talaschian, 2021 (REV) 0.80 [0.19; 3.29]
0.80 [0.19 ; 3.29 ] Talaschian, 2021 (REV) 1 0% 40 NA not evaluable clinical deteriorationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1.79 [0.83; 3.84]
1.79 [0.83 ; 3.84 ] CORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1 0% 130 NA not evaluable clinical improvementdetailed results REMAP-CAP (tocilizumab), 2021 (REV) 0.61 [0.47; 0.80]
0.61 [0.47 ; 0.80 ] REMAP-CAP (tocilizumab), 2021 (REV) 1 0% 755 NA not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1.77 [0.76; 4.12]
Veiga, 2021 (REV) 0.65 [0.28; 1.53]
1.07 [0.40 ; 2.87 ] CORIMUNO-TOCI-1 (Group 1), 2020 (REV), Veiga, 2021 (REV) 2 63% 260 moderate not evaluable recoverydetailed results Talaschian, 2021 (REV) 1.56 [0.34; 7.13]
1.56 [0.34 ; 7.13 ] Talaschian, 2021 (REV) 1 0% 36 NA not evaluable serious adverse eventsdetailed results Talaschian, 2021 (REV) 0.13 [0.01; 2.73]
Veiga, 2021 (REV) 0.60 [0.22; 1.67]
0.52 [0.20 ; 1.36 ] Talaschian, 2021 (REV), Veiga, 2021 (REV) 2 0% 165 moderate not evaluable adverse eventsdetailed results Veiga, 2021 (REV) 0.61 [0.30; 1.24]
0.61 [0.30 ; 1.24 ] Veiga, 2021 (REV) 1 0% 129 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 11:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
